Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

allogeneic hematopoietic stem cell transplantation recipient, blasts 5 percent or more of bone marrow nucleated cells, blasts 5 percent or more of peripheral blood white cells, cd22 positive, lymphoblasts 20 percent or more of bone marrow nucleated cells, lymphoblasts 20 percent or more of peripheral blood white cells, recurrent b acute lymphoblastic leukemia, refractory b acute lymphoblastic leukemia, interventional, phase1, phase2